Analyst firms · Morgan Stanley · MRTX

Morgan Stanley MRTX price target and rating history

Mirati Therapeutics Inc. (MRTX) · Health Care

Morgan Stanley rates Mirati Therapeutics Inc. (MRTX) Equal-Weight with a $140 price target, as of its latest action on Mar 1, 2022. It has published 4 rating actions on MRTX since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Equal-Weight
Price target
$140
Median target, all firms
Too few
Actions on MRTX
4

Morgan Stanley price target on MRTX

$173$157$14020222023202420252026
Morgan Stanley price target on MRTX, each point a stated target, August 2021 to March 2022.

Every Morgan Stanley rating on MRTX

Questions about Morgan Stanley and MRTX

What is Morgan Stanley's price target for MRTX?
Morgan Stanley's latest stated price target for Mirati Therapeutics Inc. (MRTX) is $140, from its action on Mar 1, 2022.
What is Morgan Stanley's rating on MRTX?
Morgan Stanley rates MRTX Equal-Weight, a neutral rating, as of Mar 1, 2022.
When did Morgan Stanley last change its view on MRTX?
On Mar 1, 2022, Morgan Stanley cuts its price target to $140 from $150, keeps Equal-Weight.

More MRTX rating histories

All Morgan Stanley ratingsMRTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.